Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial
Karen L. Kelly, John J. Crowley, Paul A. Bunn et al. · Journal of Clinical Oncology · 2001
PURPOSE: This randomized trial was designed to determine whether paclitaxel plus carboplatin (PC) offered a survival advantage over vinorelbine plus cisplatin (VC) for patients with advanced non--small-cell lung cancer. Secondary objectives were to compare toxicity, tolerability, quality of life (QOL), and resource utilization. PATIENTS AND METHODS: Two hundred two patients received VC (vinorelbine 25 mg/m(2)/wk and cisplatin 100 mg/m(2)/d, day 1 every 28 days) and 206 patients received PC (paclitaxel 225 mg/m(2) over 3 hours with carboplatin area under the curve of 6, day 1 every 21 days). Patients completed QOL questionnaires at baseline, 13 weeks, and 25 weeks. Resource utilization forms were completed at five time points through 24 months. RESULTS: Patient characteristics were similar between the groups. The objective response rate was 28% in the VC arm and 25% in the PC arm. Median survival was 8 months in both arms, with 1-year survival rates of 36% and 38%, respectively. Grade 3 and 4 leukopenia (P =.002) and neutropenia (P =.008) occurred more frequently on the VC arm. Grade 3 nausea and vomiting were higher on the VC arm (P =.001, P =.007), and grade 3 peripheral neuropathy was higher on the PC arm (P <.001). More patients on the VC arm discontinued therapy because of toxicity (P =.001). No difference in QOL was observed. Overall costs on the PC arm were higher than on the VC arm because of drug costs. CONCLUSION: PC is equally efficacious as VC for the treatment of advanced non--small-cell lung cancer. PC is less toxic and better tolerated but more expensive than VC. New treatment strategies should be pursued.
Cited by 1,123 works. doi:10.1200/jco.2001.19.13.3210
Authors
- Karen L. Kelly
- John J. Crowley
- Paul A. Bunn
- Cary A. Presant
- Patra K. Grevstad
- Carol M. Moinpour
- Scott David Ramsey
- Antoinette J. Wozniak
- Geoffrey R. Weiss
- Dennis Frederic Moore
- Valerie K. Israel
- Robert B. Livingston
- David R. Gandara
References
- Nonparametric Estimation from Incomplete Observations
- Regression Models and Life-Tables
- Regression Models and Life-Tables
- Evaluation of survival data and two new rank order statistics arising in its consideration.
- The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.
- Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
- Cancer statistics, 2000
- A Confidence Interval for the Median Survival Time
- Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrument
- Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial